RGNX

7.90

14.00% 0.97

Pre-mercato: 7.92 0.02 +0.25%

Regenxbio Inc (RGNX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$6.93

Aprire:

$7.18

Volume 24 ore:

4.81M

Relative Volume:

3.98

Capitalizzazione di mercato:

$408.41M

Reddito:

$170.44M

Utile/perdita netta:

$-193.88M

Rapporto P/E:

-2.1044

EPS:

-3.7541

Flusso di cassa netto:

$-126.38M

1 W Prestazione:

+28.87%

1M Prestazione:

+38.11%

6M Prestazione:

-40.02%

1 anno Prestazione:

-8.78%

Intervallo 1D:

$7.18

$8.73

Intervallo di 1 settimana:

$5.88

$8.73

Portata 52W:

$5.455

$16.19

Regenxbio Inc Stock (RGNX) Company Profile

Nome

Regenxbio Inc

Settore

Healthcare (1100)

Industria

Biotechnology (615)

Telefono

240-552-8181

Indirizzo

9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD

Dipendente

371

Cinguettio

@REGENXBIO

Prossima data di guadagno

2026-08-06

Ultimi documenti SEC

RGNX's Discussions on Twitter

Compare RGNX vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RGNX Regenxbio Inc	7.90	365.50M	170.44M	-193.88M	-126.38M	-3.7541
VRTX Vertex Pharmaceuticals Inc	458.99	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	607.93	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	892.26	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.72	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.77	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-28	Ripresa	Barclays	Overweight
2025-02-11	Downgrade	Goldman	Buy → Neutral
2025-02-07	Ripresa	Raymond James	Outperform
2024-11-15	Ripresa	Morgan Stanley	Overweight
2024-10-10	Ripresa	Raymond James	Outperform
2024-06-07	Iniziato	Goldman	Buy
2024-03-11	Iniziato	H.C. Wainwright	Buy
2024-03-08	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2024-03-06	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-02-21	Ripresa	Raymond James	Outperform
2023-11-01	Iniziato	Stifel	Buy
2023-06-02	Iniziato	Robert W. Baird	Outperform
2022-06-23	Iniziato	Berenberg	Buy
2021-12-15	Iniziato	Wedbush	Neutral
2021-10-19	Ripresa	Morgan Stanley	Overweight
2021-01-06	Aggiornamento	Raymond James	Outperform → Strong Buy
2020-12-16	Iniziato	UBS	Buy
2020-06-25	Ripresa	BofA/Merrill	Buy
2020-05-13	Iniziato	RBC Capital Mkts	Sector Perform
2019-08-20	Aggiornamento	SVB Leerink	Underperform → Mkt Perform
2019-06-18	Reiterato	Chardan Capital Markets	Buy
2019-06-14	Ripresa	Raymond James	Outperform
2019-06-05	Reiterato	Chardan Capital Markets	Buy
2019-02-25	Aggiornamento	Evercore ISI	In-line → Outperform
2019-02-05	Aggiornamento	Raymond James	Outperform → Strong Buy
2018-12-17	Reiterato	Chardan Capital Markets	Buy
2018-11-08	Reiterato	BofA/Merrill	Neutral
2018-08-08	Reiterato	Chardan Capital Markets	Buy
2018-07-23	Downgrade	BofA/Merrill	Buy → Neutral
2018-07-10	Reiterato	Chardan Capital Markets	Buy
2018-05-09	Reiterato	Barclays	Overweight
2018-04-09	Reiterato	Chardan Capital Markets	Buy
2018-03-12	Downgrade	Evercore ISI	Outperform → In-line
2018-02-13	Iniziato	Mizuho	Neutral
2017-11-09	Ripresa	Morgan Stanley	Overweight

Mostra tutto

Regenxbio Inc Borsa (RGNX) Ultime notizie

Jun 15, 2026

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy - Eastern Progress

Jun 15, 2026

Jun 14, 2026

Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Eastern Progress

Jun 14, 2026

FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits

Jun 14, 2026

Jun 11, 2026

Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax - Barchart.com

Jun 11, 2026

Jun 08, 2026

H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $26 - Moomoo

Jun 08, 2026

H.C. Wainwright lowers Regenxbio stock price target on trial data By Investing.com - Investing.com South Africa

Jun 08, 2026

H.C. Wainwright lowers Regenxbio stock price target on trial data - Investing.com

Jun 08, 2026

Jun 06, 2026

Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Climb Bio (CLYM) - The Globe and Mail

Jun 06, 2026

Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits

Jun 05, 2026

H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $26 - Moomoo

Jun 05, 2026

RGNX Maintains Rating by HC Wainwright & Co. -- Price Target Lowered to $26 - GuruFocus

Jun 05, 2026

Regenxbio slides after late-stage trial data for Duchenne therapy - MSN

Jun 05, 2026

Jun 04, 2026

JPMorgan affiliates report 4.4% stake in REGENXBIO (RGNX) in 13G/A - Stock Titan

Jun 04, 2026

Jun 03, 2026

REGENXBIO (RGNX) offers exchange of 2.9M eligible options for replacements - Stock Titan

Jun 03, 2026

REGENXBIO (NASDAQ: RGNX) investors back board, reject executive option swap - Stock Titan

Jun 03, 2026

Jun 02, 2026

REGENXBIO (RGNX) awards director Daniel Tasse RSUs and options - Stock Titan

Jun 02, 2026

REGENXBIO (RGNX) director receives new RSU and stock option awards - Stock Titan

Jun 02, 2026

[Form 4] REGENXBIO Inc. Insider Trading Activity - Stock Titan

Jun 02, 2026

REGENXBIO (RGNX) director Kenneth Mills granted RSUs and 46,600 stock options - Stock Titan

Jun 02, 2026

REGENXBIO (RGNX) director awarded 9,807 RSUs and 46,600 stock options - Stock Titan

Jun 02, 2026

Director at REGENXBIO (RGNX) receives RSU and option grants - Stock Titan

Jun 02, 2026